Billing Under New York's Three-Cycle IVF Mandate: Plan-Funding Verification and Carrier Auth Workflows

New York requires fully insured large-group plans to cover three cycles of IVF, and the Department of Financial Services (DFS) guidance allows insurers to limit that coverage to three cycles over the life of the insured. What makes the New York benefit operationally distinct is how the statute defines a cycle: it is all treatment that starts when medications are given either for ovarian stimulation with the intent of a fresh transfer, or for endometrial preparation with the intent of a frozen transfer. That definition decides which encounters consume one of the patient's three cycles, so cycle tracking, authorizations, and documentation have to be built around it rather than around retrieval counts alone.

This post covers the statutory foundation of the New York mandate, the scope of covered services, applicable CPT and ICD-10 codes, carrier-specific prior authorization requirements for the major New York commercial carriers, FET billing rules, same-sex couple and single patient protocols, and the highest-impact billing errors that generate claim denials under NY mandate plans.

The Statutory Foundation: New York Insurance Law §3221(k)(6)

New York's IVF requirement is codified in New York Insurance Law §3221(k)(6)(C) for group policies and §4303(s)(3) for contracts issued under Article 43. It was enacted by Part L of Chapter 57 of the Laws of 2019 and applies to policies and contracts issued or renewed in New York on or after January 1, 2020. DFS published Q&A guidance on the IVF and fertility preservation law to explain how carriers must apply it. The statute requires group accident and health insurance policies that provide coverage for hospital or medical expenses to include coverage for the diagnosis and treatment of infertility, including in vitro fertilization, for covered employees and dependents who meet the statutory criteria. For large-group policies, the statute requires coverage for three cycles of IVF used in the treatment of infertility, and DFS guidance confirms that issuers may limit coverage to three cycles over the life of the insured.

The IVF requirement applies to large-group policies delivered or issued for delivery in New York; DFS defines large group as a group of more than 100 employees. Individual policies and small-group plans (100 or fewer employees) are not subject to the IVF requirement, though some carriers include fertility benefits in small-group products voluntarily or pursuant to other plan terms. As with all state insurance mandates, the federal ERISA preemption provision exempts self-funded employer health plans from state mandate compliance. A plan's ERISA-governed status is determined by the source of funding — employer contributions bearing the financial risk versus premium payments to a licensed insurer — not by which insurance company's name appears on the member ID card. Confirming plan funding type at every initial eligibility verification is not optional for New York fertility practices; it is the foundational step on which all subsequent coverage determinations depend.

Plan Eligibility: Which New York Plans Are Subject to the Mandate

A New York plan is subject to the IVF mandate if it meets all three of the following: (1) it is a group accident and health insurance policy or managed care contract issued, delivered, or renewed in New York State; (2) it is a large group of more than 100 employees; and (3) it is fully insured — meaning the licensed insurer bears the financial risk, not the employer. When all three conditions are met, the plan must cover three cycles of IVF. When any one condition is absent, the mandate does not apply: a self-funded plan covering 10,000 New York employees has no mandate obligation; a 200-employee group plan issued in New Jersey that covers a New York-based employee is subject to New Jersey's mandate, not New York's; and an individual or family plan is subject to different NY individual market fertility coverage rules.

In New York City and the surrounding metropolitan area, the mix of self-funded and fully insured large-group plans skews heavily toward self-funded for employers with 500 or more employees. Major financial institutions, law firms, hospital systems, and technology companies commonly self-fund their health benefits even when those plans are administered by Empire BlueCross, Aetna, or UHC. The presence of a New York address and a recognizable carrier on the insurance card is not sufficient to assume mandate coverage. Staff must ask the carrier's eligibility line directly — "Is this plan fully insured or self-funded?" — document the answer with the representative's name and the date, and not proceed with cycle services until the plan funding type is confirmed in the billing record.

Covered Fertility Services Under the New York Mandate

New York's mandate requires coverage for the diagnosis and treatment of infertility. Covered services include the full spectrum of clinically recognized infertility evaluation and treatment:

• Infertility diagnostic workup: comprehensive baseline labs (FSH 83001; LH 83002; estradiol 82670; AMH; prolactin 84146; TSH 84443), semen analysis (89300 — presence and/or motility of sperm including the Huhner post-coital test; 89310 — motility and count; 89320 — volume, count, motility, and differential; 89322 — volume, count, motility, and differential using strict morphologic criteria, e.g., Kruger), hysterosalpingography (74740 for fluoroscopic or 58340 for sonographic/office-based), antral follicle count by transvaginal ultrasound (76830), diagnostic hysteroscopy (58555), diagnostic laparoscopy (49320 or 58660), and endometrial biopsy (58100)
• IVF — complete fresh cycle including controlled ovarian stimulation, follicle ultrasound monitoring (76817 transvaginal; 76830 transabdominal), serial estradiol and LH monitoring labs, oocyte retrieval (58970) with ultrasound guidance (76948), conventional oocyte insemination (89268), ICSI (89280 for ≤10 oocytes; 89281 for >10 oocytes), embryo culture (89250), extended embryo culture to blastocyst (89272), and embryo transfer (58974)
• Frozen embryo transfer (FET): embryo cryopreservation (89258), embryo thaw and preparation (89352), and FET embryo transfer procedure (58974); DFS guidance counts the planned first transfer of embryos frozen during an IVF cycle as part of that cycle, and a frozen transfer that starts with endometrial preparation medications is a cycle of its own. Aetna's infertility precertification form lists FET as its own requested service, and UHC's commercial prior authorization list includes 89352 and 58974, so confirm with each carrier whether FET goes on the cycle authorization or needs a separate request
• IUI (intrauterine insemination): sperm wash and preparation (89260) and the insemination procedure (58322); the mandate covers IUI, though plan-level IUI cycle limits may apply within the mandate framework
• Preimplantation genetic testing (PGT): embryo biopsy for PGT (89290 for ≤5 embryos; 89291 for >5 embryos); neither §3221(k)(6) nor the DFS Q&A addresses PGT, so coverage and criteria come from the plan and the carrier's medical policy. UnitedHealthcare's commercial prior authorization list includes 89290 and 89291, and Aetna's infertility precertification form lists PGT-A and PGT-M/PGT-SR as their own requested services, asking for genetic testing results with PGT-M/PGT-SR requests
• Iatrogenic fertility preservation: oocyte cryopreservation (89337) prior to gonadotoxic treatment (chemotherapy, pelvic radiation, or surgical intervention threatening ovarian function) is covered using Z31.84 as the first-listed code with the oncology diagnosis after it — never use N97.x infertility diagnosis codes for iatrogenic preservation patients, as this triggers a medical necessity review under infertility criteria that the patient will fail
• Ovarian reserve testing as a covered diagnostic service: AMH testing, antral follicle count by transvaginal ultrasound (76830), and Day 3 FSH, LH, and estradiol panels

Services not required to be covered under the NY mandate include: elective (social) egg freezing performed in the absence of a medical indication that threatens future fertility; third-party donor egg acquisition fees or compensation paid directly to an egg donor; third-party sperm donor purchase fees (though the insemination procedure itself is covered); gestational carrier or surrogacy fees paid to the carrier; and any procedure classified as investigational or experimental under the carrier's current fertility medical policy. Storage is not on that list. The DFS Q&A states that issuers must cover medically necessary oocyte and/or embryo storage in connection with an intended IVF procedure until the three required IVF cycles are provided (Q-8), and if the patient changes carriers with embryos in storage, the new issuer covers the storage costs once the patient is eligible for IVF benefits under its policy (Q-23). For fertility preservation patients, the law sets no specific limit on how long ova or sperm may be stored (Q-37). The IVF storage requirement runs only until the three required cycles are provided, and the Q&A does not address sperm storage for IVF outside fertility preservation. For storage beyond those points, confirm the plan benefit and have a signed storage financial agreement on file before billing the patient.

CPT Code Reference for New York Mandate Fertility Services

ICD-10 Diagnosis Coding for New York Mandate Claims

New York mandate claims require ICD-10 codes that accurately reflect the patient's infertility diagnosis and etiology. Carriers use the primary diagnosis code to route the claim to the fertility benefit and validate medical necessity. Using an unspecified code when a specific etiology is documented increases the risk of supplemental documentation requests and delays reimbursement. For IVF cycle claims, the primary diagnosis should be the most specific female infertility code consistent with the documented clinical findings; secondary codes should include applicable etiologic, procedural, and encounter codes.

Primary infertility diagnosis codes: N97.0 (female infertility associated with anovulation — use for PCOS, hypothalamic dysfunction, anovulatory cycles; add E28.2 as secondary when PCOS is the specific etiology); N97.1 (female infertility of tubal origin — documented tubal occlusion, prior ectopic pregnancy, prior salpingectomy, tubal ligation reversal); N97.2 (female infertility of uterine origin — uterine anomaly, Asherman's syndrome, submucosal fibroid as primary cause); N97.8 (female infertility of other or combined origin — when two distinct etiologies are present, or etiology does not fit a more specific category); N97.9 (female infertility, unspecified — use only when no etiology can be documented; the weakest code for medical necessity defense, and carriers may require supplemental documentation when this code appears as the primary). Male factor supporting codes: N46.01 (organic azoospermia), N46.11 (organic oligospermia), N46.021–N46.029 (azoospermia by etiology), N46.121–N46.129 (oligospermia by etiology). Encounter codes: Z31.83 (encounter for assisted reproductive fertility procedure cycle) — the first-listed code on every IVF and FET cycle claim, ahead of the infertility codes above (ICD-10-CM Official Guidelines, Section I.C.21.c.15); Z31.41 (encounter for fertility testing) — for diagnostic workup claims; Z31.84 (encounter for fertility preservation procedure) — for fertility preservation encounters. For iatrogenic fertility preservation, Z31.84 is the first-listed code (the same guideline section allows it only in that position), followed by the oncology code (e.g., C50.x for breast cancer; C56.x for ovarian cancer); N97.x infertility codes must never appear on these claims. For same-sex couple and single patient IVF cycles where no infertility diagnosis exists (the patient is reproductively competent but requires donor sperm), list Z31.83 first with Z31.89 (encounter for other procreative management) after it.

Prior Authorization Requirements by Major New York Carrier

DFS guidance allows issuers to require preauthorization for IVF services, and the carriers below publish prior authorization requirements for infertility treatment. Which services need their own request (FET, ICSI, PGT, IUI) and where the request goes differ by carrier and product; a request sent to the wrong entity or portal leaves no valid authorization on file, and the claim denies at adjudication even when the service is mandate-compliant and clinically appropriate.

• Empire BlueCross BlueShield (Anthem NY) — DFS guidance allows issuers to require preauthorization for IVF services, so confirm Empire's fertility PA requirement and submission route for the specific product at every initial eligibility verification, and record where the request was sent. Do not assume that fertility PA is delegated to a utilization management vendor; confirm the route with Empire for that product. Confirm whether FET and PGT need their own authorizations or fall under the IVF cycle authorization, and note the approval's validity window in the billing record. The PA package should document the infertility diagnosis and etiology, duration of infertility, prior treatment history, and the treating physician's treatment plan.
• UnitedHealthcare (UHC) New York — UHC's commercial prior authorization requirements list infertility diagnosis and treatment codes that require PA, including IUI (58322), oocyte retrieval (58970), embryo transfer (58974), ICSI (89280, 89281), PGT biopsy (89290, 89291), and embryo thaw (89352). UHC directs these requests to the Prior Authorization and Notification tool on the UnitedHealthcare Provider Portal. Optum Fertility Solutions is a separate clinical support and medical management program that some employer plans use; UHC states it also pays claims when the program is not used, so confirm at eligibility verification whether the member's plan sends fertility requests to Optum Fertility Solutions or to the UHC portal. UHC's Infertility Diagnosis, Treatment, and Fertility Preservation medical policy refers medical necessity reviews to the Optum Fertility Solutions infertility clinical guideline.
• Aetna New York — Aetna's Infertility Services Precertification Information Request Form goes to Aetna's own Precertification Department, with questions routed to Aetna's Infertility Department, and Aetna prefers electronic requests through its Availity provider portal. The form asks for the treatment plan, cycle day 3 FSH and estradiol drawn within the past 6 months, time trying to conceive or the history that led to the diagnosis, all previous IUI cycles, and embryology reports for additional ART cycle requests, and should be completed at least 15 days before the planned start date. The form lists IUI, IVF, IVF freeze-all, ICSI, assisted hatching, FET, PGT-A and PGT-M/PGT-SR as separate requested services, and Aetna reviews them against Clinical Policy Bulletins 0327 (Infertility) and 0358. CPB 0327 includes IUI trial requirements for some diagnoses — if IUI was attempted and failed, include those records; if IUI was clinically contraindicated, include the treating physician's written contraindication statement explicitly noting the clinical basis. Aetna notes that prior treatment approval does not guarantee approval for ongoing or future treatment.
• Cigna New York — Cigna Medical Coverage Policy 0089 (Infertility Services) lists IVF and ICSI among covered treatment services where the plan has an infertility benefit, and its coverage criteria do not set an IUI cycle count as a prerequisite for IVF. The policy also says delegated vendor guidelines may be used in certain markets, so confirm with Cigna at eligibility verification where fertility requests for the member's product are submitted and which services (FET, PGT) need their own request.
• MVP Health Care — MVP's provider notice on the 2020 law applies the IVF benefit to members with large group commercial coverage through MVP, with prior authorization, from the plan's renewal. MVP asks for prior authorization of both the IVF procedure and the fertility medications, and the procedure authorization must be approved before the medications are authorized; approved medications are filled through MVP's contracted specialty pharmacy. MVP's current list of services that require prior authorization includes advanced infertility services including IVF and infertility drug therapy. Confirm the member's plan coverage with MVP provider services before the cycle starts.
• Fidelis Care — Fidelis's published plan lineup is Medicaid Managed Care, Child Health Plus, the Essential Plan, HealthierLife (HARP), Medicaid Advantage Plus, Ambetter from Fidelis Care Qualified Health Plans, managed long-term care, and Wellcare Medicare; it lists no employer group plans. The three-cycle IVF requirement applies to large-group policies, so for a Fidelis member, confirm the product and its own fertility benefit at eligibility rather than assuming the IVF mandate applies.

FET Billing Under New York Mandate Plans

FET billing is a recurring source of claim denials in New York practices. Knowing that the first frozen transfer after a freeze-all retrieval falls within the same mandate cycle does not tell you whether the retrieval authorization covers the FET codes (89352 for embryo thaw; 58974 for the transfer). Carriers handle this differently: Aetna's infertility precertification form lists FET as its own requested service, and UHC's commercial prior authorization list includes both 89352 and 58974. For other carriers, ask at eligibility verification whether FET is authorized under the IVF cycle request or needs its own request, and record the answer. Before the FET monitoring cycle begins, confirm that an active authorization lists the FET codes, and include the embryo inventory and cycle plan with any FET request.

Frozen transfers count against the three-cycle limit differently depending on where they fall. Under DFS guidance, the planned first transfer of embryos frozen during an IVF cycle is part of that cycle, while a frozen transfer that begins with endometrial preparation medications is its own cycle under the statutory definition. Confirm with each carrier at initial eligibility verification how it applies that definition and whether the plan offers FET coverage beyond the mandate. Collect the FET benefit details (cycle limit if any, authorization requirement, and clinical criteria) separately from the IVF retrieval benefit at initial eligibility verification. Do not assume FET benefit rules mirror retrieval benefit rules. For patients transferring frozen embryos from another clinic, obtain written records of prior FET cycles at the previous facility and confirm with the current insurer whether those cycles have been applied to any benefit limit.

Same-Sex Couples and Single Patients Under the NY Mandate

The infertility definition quoted in the DFS guidance counts therapeutic donor insemination (TDI) the same way as intercourse: infertility is the failure to establish a clinical pregnancy after 12 months of regular, unprotected sexual intercourse or therapeutic donor insemination, or after six months for a female 35 years of age or older. Same-sex couples and single patients therefore document infertility through TDI history rather than intercourse history. The definition is stated in months and sets no count of insemination cycles; any cycle count, or any allowance for proceeding directly to IVF on clinical grounds, comes from the carrier's clinical criteria, so confirm the carrier's requirement before building the PA package. PA documentation for same-sex and single patient authorizations typically includes:

• Records of all prior physician-supervised TDI or monitored insemination cycles, including dates, protocol, outcomes, and supervising provider — collect from all prior treating clinics, not only your own facility
• The treating REI physician's written statement documenting the TDI protocol and outcomes, or, where the carrier's criteria allow proceeding directly to IVF, an explicit clinical justification that cites the documented findings (for example, ovarian reserve results, bilateral tubal occlusion, or prior failed inseminations) and the carrier criterion they meet
• Confirmation that the insemination cycles used donor sperm or partner gametes as appropriate and were physician-supervised — self-insemination cycles do not qualify under most carrier clinical criteria and may prompt a request for documentation of supervising provider records
• For same-sex female couples where one partner carries and one partner provides oocytes (reciprocal IVF or RIVF): confirm with each partner's carrier, before the cycle starts, which partner's coverage it will apply to the retrieval and which to the transfer, and whether either plan covers services for a partner who is not the patient with the infertility diagnosis; record the answer and bill accordingly rather than assuming a default split
• ICD-10 coding for same-sex and single patient IVF with no infertility diagnosis: list Z31.83 (encounter for assisted reproductive fertility procedure cycle) first with Z31.89 (encounter for other procreative management) after it; when a co-existing infertility diagnosis is present (e.g., diminished ovarian reserve in a same-sex female patient), list Z31.83 first with the specific N97.x code after it

Common New York Mandate Billing Errors and Prevention

• Assuming mandate coverage for self-funded plans: The most costly billing error in New York fertility practices. ERISA self-funded plans are not subject to the NY mandate. A recognizable carrier name on the member ID card does not indicate fully insured status. Prevention: confirm fully insured status at every initial eligibility call; document the response, representative name, and date; flag self-funded patients separately in your billing system before any cycle services are authorized or rendered.
• Billing FET codes against an authorization that does not include them: Aetna's precertification form treats FET as its own requested service and UHC lists 89352 and 58974 as requiring prior authorization, so a retrieval authorization alone may not cover the FET. Prevention: build an FET authorization check that runs when a freeze-all cycle completes, when PGT results are received, or when a fresh transfer is cancelled due to OHSS risk or embryo quality concerns, and confirm an authorization listing the FET codes is on file before the FET monitoring cycle begins.
• Sending a fertility PA to the wrong entity: A request filed with a portal or vendor the plan does not use for fertility produces no authorization on file, and the claim denies for lack of PA. Prevention: confirm the fertility PA route for each carrier and product at eligibility verification, record it in the patient's billing file, and audit carrier-to-vendor routing annually.
• Billing PGT biopsy codes (89290, 89291) against an authorization that does not include them: UHC lists both codes as requiring prior authorization, and Aetna's precertification form treats PGT as its own requested service, so a retrieval authorization alone may not cover the biopsy. Prevention: whenever PGT is planned, confirm with the carrier whether PGT goes on the cycle request or a separate one, and confirm an authorization covering the biopsy codes is on file before submitting biopsy claims.
• Using infertility ICD-10 codes for iatrogenic fertility preservation patients: Applying N97.x to an oncology patient's pre-chemotherapy egg freeze triggers a medical necessity review under infertility criteria that the patient cannot satisfy. The claim denies. Prevention: build a clinical trigger in your intake workflow that identifies patients undergoing gonadotoxic treatment and routes their claims to the iatrogenic preservation coding protocol (Z31.84 first-listed + oncology diagnosis).
• Submitting a new IVF retrieval PA when the patient has a viable cryopreserved embryo inventory: NY carriers may deny a new retrieval PA when the patient has frozen embryos available, on the grounds that a clinically equivalent and less invasive alternative (FET) exists. Prevention: review embryo inventory before submitting a retrieval PA for any patient with frozen embryos; include the physician's clinical rationale for new retrieval in the PA package (e.g., poor embryo quality, insufficient embryo number, prior failed FETs from the existing inventory, change in clinical protocol).
• Missing or incomplete TDI documentation for same-sex and single patient authorization packages: PA packages submitted without complete supervised TDI records are returned for supplemental documentation, delaying the authorization. Prevention: create a same-sex and single patient intake checklist with prior TDI documentation collection as a required step; assign responsibility to a specific staff member with a defined collection deadline before the PA submission date.
• Not requesting expedited PA review when a cycle is time-sensitive: A PA submitted late may not be decided before the patient's optimal stimulation window. Prevention: request expedited review for any PA submitted within 5 business days of the anticipated cycle start date; document the clinical basis for expedited review (age, cycle day, ovarian reserve metrics) in the submission.

Appealing New York Mandate Coverage Denials

New York fully insured plans are subject to robust external appeal rights under New York Insurance Law and the ACA. New York Insurance Law §4904 requires utilization review agents to allow at least 45 days after the insured receives the initial determination to file an internal appeal, and the plan's adverse determination notice states the actual deadline, so calendar the date from that notice. After exhausting the plan's internal appeal process, patients and providers may request an external independent review through the New York State Department of Financial Services (DFS) or, for HMO plans, through a DFS-approved independent review organization (IRO). External review decisions in New York are binding on fully insured insurers. Self-funded ERISA plans are not subject to the New York DFS process; ERISA plans have limited federal external review rights under the ACA's external review regulations.

For NY mandate medical necessity denials, the internal appeal package should include: the complete infertility workup documentation establishing diagnosis and etiology; confirmation that the patient meets the New York statutory infertility definition (including TDI cycle records for same-sex and single patients); prior treatment history relevant to the proposed service; the treating REI physician's signed letter of medical necessity; applicable ASRM Practice Committee Opinion guidelines supporting the requested service for the patient's specific diagnosis; peer-reviewed literature; and a written argument identifying where the carrier's denial conflicts with New York Insurance Law §3221(k)(6) and the DFS implementing guidance. For denials applying an IUI cycle prerequisite to a patient with a documented IUI contraindication, include the physician's written contraindication statement and show where the carrier's own published criteria do not require IUI for that diagnosis. If the carrier issued the adverse determination without attempting to discuss it with the ordering provider, New York Insurance Law §4903(f) lets that provider request a reconsideration, which must occur within one business day of the request (except for retrospective reviews) and is conducted between the provider and the clinical peer reviewer. For time-sensitive cycles, also ask for an expedited appeal: §4904 requires expedited appeals to be decided within two business days of receipt of the necessary information. Document the verbal outcome of every peer-to-peer immediately after the call and follow up in writing if a revised authorization is not issued.

Quarterly Billing Audit Checklist for New York Practices

A quarterly audit of New York mandate billing should confirm: every IVF, FET, PGT, and monitored IUI claim has a matching authorization number on file before submission; each fertility PA was sent to the route the carrier confirmed for that product; plan funding type is documented at the patient level and confirmed as fully insured before any cycle services are authorized; FET claims (89352, 58974) are covered by an authorization that lists those codes, whether a separate FET request or the cycle authorization, as the carrier confirmed; same-sex and single patient files contain complete supervised TDI documentation collected before the PA submission date; PGT biopsy claims (89290, 89291) are covered by an authorization that includes those codes; iatrogenic preservation claims list Z31.84 first with the oncology diagnosis after it — not N97.x codes; new retrieval PAs for patients with a frozen embryo inventory include a physician-authored rationale for retrieval over FET; all denial-to-internal-appeal turnaround times are within the plan-specific internal appeal deadline; and external review eligibility is tracked for all internally upheld denials to ensure patients do not forfeit DFS appeal rights by missing the submission deadline.